SARS-CoV-2 in the Air Surrounding Patients during Nebulizer Therapy

Jostein Gohli 1, Arne Broch Brantsæter 2,3, Kari Oline Boifot 1,4, Carola Grub 5, Beathe Kiland Granerud 6,7,8, Jan Cato Holter 6,8, Anne Margarita Dyrhøl Riise 2,8, Madelen Foss Smådalen 9 and Marius Dybwad 1,4

1 Norwegian Defence Research Establishment, P. O. Box 25, No. 2027 Kjeller, Oslo, Norway
2 Department of Infectious Diseases, Oslo University Hospital, P. O. Box 4956, Nydalen, No. 0424, Oslo, Norway
3 Norwegian National Unit for CBRNE Medicine, Oslo University Hospital, P. O. Box 4956, Nydalen, No. 0424, Oslo, Norway
4 Department of Analytics, Environmental & Forensic Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK
5 Institute of Microbiology, Norwegian Armed Forces Joint Medical Services, P. O. Box 25, No. 2027, Kjeller, Oslo, Norway
6 Department of Microbiology, Oslo University Hospital, P. O. Box 4950, Blindern, No. 0424, Oslo, Norway
7 Department of Nursing, Health and Laboratory Science, University College of Østfold, P. O. Box 700, No. 1757, Halden, Oslo, Norway
8 Institute of Clinical Medicine, University of Oslo, P. O. Box 1171, Blindern, No. 0318, Oslo, Norway
9 Oslo University Hospital, P. O. Box 4950, Nydalen, No. 0424, Oslo, Norway

Correspondence should be addressed to Jostein Gohli; jostein.gohli@gmail.com

Received 10 June 2022; Revised 5 August 2022; Accepted 29 August 2022; Published 17 September 2022

Academic Editor: Mohd Adnan

Copyright © 2022 Jostein Gohli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nebulizer therapy is commonly used for patients with obstructive pulmonary disease or acute pulmonary infections with signs of obstruction. It is considered a “potential aerosol-generating procedure,” and the risk of disease transmission to health care workers is uncertain. The aim of this pilot study was to assess whether nebulizer therapy in hospitalized COVID-19 patients is associated with increased dispersion of SARS-CoV-2. Air samples collected prior to and during nebulizer therapy were analyzed by RT-PCR and cell culture. Total aerosol particle concentrations were also quantified. Of 13 patients, seven had quantifiable virus in oropharynx samples, and only two had RT-PCR positive air samples. For both these patients, air samples collected during nebulizer therapy had higher SARS-CoV-2 RNA concentrations compared to control air samples. Also, for particles sizes 0.3–5 µm, particle concentrations were significantly higher during nebulizer therapy than in controls. We were unable to cultivate virus from any of the RT-PCR positive air samples, and it is therefore unknown if the detected virus were replication-competent; however, the significant increase in smaller particles, which can remain airborne for extended periods of time, and increased viral RNA concentrations during treatment may indicate that nebulizer therapy is associated with increased risk of SARS-CoV-2 transmission.

1. Introduction

Since the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a global pandemic on March 11th, 2020 [1], the virus has caused more than 418 million diseased cases and over 5.8 million deaths [2] worldwide.

The 2003 outbreak of SARS-CoV-1 and the ongoing MERS-CoV epidemic have demonstrated that health care workers (HCW) are at risk of nosocomial infection [3]. The level of environmental SARS-CoV-2 contamination, both in air and on surfaces, is significantly higher in hospitals as compared to other environments [4]. Unsurprisingly, COVID-19 has disproportionality affected HCW [5–8], resulting in reduced treatment capacity and additional strain...
on already overburdened health care systems [9]. Therefore, appropriate infection prevention and control measures such as personal protective equipment and vaccination of HCW are of utmost importance. However, while the majority of HCW in high-income countries are vaccinated, only 27% in Africa are fully vaccinated [10]. Vaccinations significantly reduce, but do not remove the risk of symptomatic infection [11, 12], asymptomatic infection [12, 13], transmission [12], or even severe illness [12, 13]. Therefore, to prevent HCW from infection with SARS-CoV-2, identifying high-risk procedures is important.

Aerosol-generating procedures (AGP) produce small respiratory particles. While no universally accepted list of AGP exists [14], the WHO includes procedures such as intubation, cardiopulmonary resuscitation, bronchoscopy, and surgery involving the use of high-speed devices [15]. The potential link between AGP and transmission of acute respiratory infection has long been debated [16–18], and the current pandemic has sparked further controversy [19, 20], including the potential risk of SARS-CoV-2 transmission to HCW [21–24]. Aerosol particles are very small particles that may stay suspended in the air for some time and have the ability to travel distances >2 meters [25]. The upper size limit of what constitutes an aerosol particle is context-dependent and in no way absolute—different operational definitions include particles of widely different sizes [26]. Since small aerosol particles can penetrate and circumvent surgical masks, AGP may necessitate the use of N95 or higher protection respirators and eye protection [19]. Optimally, AGP performed in patients with acute respiratory tract infections should be carried out in airborne infection isolation rooms with frequent air changes and negative pressure [27]. It is worth noting that the risk associated with AGP is not a simple function of the number of aerosol particles produced but is dependent on a number of factors that may contribute to transmission risks such as the size distribution of aerosol particles [28], the amount of force applied on air over a moist respiratory mucous membrane, and the virus load in the involved tissues [19].

Nebulizer therapy (NT) is often used in the treatment of patients with chronic obstructive pulmonary disease and to relieve symptoms in patients with acute pulmonary infection with cough and signs of obstruction. NT changes medication from liquid to an inhalable mist. NT is considered a “possible aerosol-generating procedure,” but whether NT represents an increased infection risk for HCW is still controversial [18, 19, 29]. Since aerosols are produced from medication during NT, and not from patient tissues, some argue that there is no associated increased risk of transmission [30]. However, the jet applied during NT can potentially also induce aerosol generation from infected tissue fluids [31], leading to room contamination by exhaled air, which was the likely driving factor in one hospital outbreak of SARS-CoV-1 in 2003 [32]. Therefore, it has been argued that NT is a significant risk factor for SARS-CoV-2 transmission [33, 34]. However, very limited evidence exists to support either view [35].

In this pilot study, we explored the impact of NT on the concentration level of total aerosol particles and SARS-CoV-2 in the air surrounding hospitalized COVID-19 patients receiving such treatment.

2. Methods

2.1. Study Participants. This pilot study was conducted at Oslo University Hospital (OUH) in collaboration with a prospective observational cohort study of hospitalized adults (aged ≥18 years) with COVID-19. “The Norwegian SARS-CoV-2 study – virological, clinical, and immunological characterization of inpatients during the COVID-19 outbreak” (ClinicalTrials.gov Identifier: NCT04381819 [36]). Thirteen COVID-19 patients admitted to the ward at the Department of Infectious Diseases, OUH were included. Five were female and eight were male, with a mean age of 55.3 years (min = 37, max = 81; Table 1). None of the participants were vaccinated for COVID-19. Informed consent was given by all patients or from next of kin if patients were incapacitated and therefore unable to give consent. The pilot study was approved by the Regional Committees for Medical and Health Research Ethics in South-Eastern Norway (reference no. 106624).

2.2. Collection of Air Samples. All patients were admitted to an airborne-precaution room with >22 exchanges of air/hour and negative pressure of 30 Pa with reference to the ordinary clinical areas of the ward. NT was given with Philips Respironics SideStream disposable kits (Respironics Respiratory Drug Delivery Ltd., Chichester, UK) with an oxygen flow of 8L/min. The NT procedure lasted for approximately 10 minutes and consisted of inhalation of a mixture of 2.5 ml of salbutamol 1 mg/ml and 1 ml of ipratropium bromide 0.25 mg/ml.

Air samples from the isolation rooms were collected immediately prior to and during NT. Air sampling was conducted on average 13.4 (median = 12; range 7–23; Table 1) days after symptom onset. First, the air was sampled for 15 minutes prior to the administration of NT (hereafter referred to as the “control sample”). Then, a second 15-minute air sample was collected, starting from the beginning of the NT. Talking, mild coughing, severe coughing, laughing, and sneezing was recorded during air sampling (Table 1). Air samples were collected on electret filters with SASS3100 air samplers (300 L of air per minute; Research International, Monroe, WA, USA). The air samplers were placed at the foot end of the bed, at a height of 1.2 meters with a 45° downward angle to avoid deposition of larger respiratory droplets on the filters. The SASS inlet was cleaned with ethanol wipes before the filters were mounted. For both the control and the NT samples, two SASS air samplers were used in parallel—one filter was analyzed with RT-PCR and one with cell culture. Air filters for RT-PCR were transported on blue ice to the laboratory in 50 ml sterile vials containing 10 ml of NucliSENS lysis buffer (BioMérieux, Marcy-l’Etoile, France) and stored at −80°C until further processing. Air filters for cell culture were placed directly in 50 ml sterile vials containing 10 ml of Dulbecco’s modified essential medium (DMEM, Sigma) with 1% penicillin/
Table 1: All analyzed data.

| Age  | Sex       | Date of symptom onset | Date of sample collection | Days after symptom onset | Potential aerosol-generating behavior during control sample period (before NT) | Potential aerosol-generating behavior during NT sample period | Control sample (before NT) | NT sample | Date of sample collection | Days after symptom onset | Viral load/1000 cells |
|------|-----------|-----------------------|---------------------------|--------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------|-----------|--------------------------|------------------------|------------------------|
| 35-40| Female    | 14.10.2020            | 06.11.2020                | 23                       | 0 0 0 0 0                      | 1 0 0 0 0                      | —                        | —         | 28.10.2020               | 14                     | 3                     |
| 65-70| Male      | 19.11.2020            | 30.11.2020                | 11                       | 3 0 0 0 0                      | 0 0 0 0 0                      | —                        | —         | 29.11.2020               | 10                     | 1 780                  |
| 60-65| Male      | 19.11.2020            | 30.11.2020                | 11                       | 15 1 0 0 0                     | 0 0 2 0 0                      | 36* 35* 31.81 ± 0.02 31.97 ± 0.06 | —         | 23.11.2020               | 4         | 69 942                  |
| 50-55| Male      | 11.11.2020            | 30.11.2020                | 19                       | 15 0 0 0 0                     | 1 1 0 0 0                      | —                        | —         | 29.11.2020               | 10                     | —                     |
| 45-50| Male      | 02.01.2021            | 11.01.2021                | 9                        | 15 0 0 0 0                     | 4 11 0 0 0                     | 35.79 ± 0.02              | —         | 20.01.2021               | 7                      | 13                    |
| 80-85| Male      | 01.01.2021            | 11.01.2021                | 10                       | 15 0 0 0 0                     | 7 0 0 0 0                      | —                        | —         | 20.01.2021               | 10                     | 0                     |
| 50-55| Female    | 01.01.2021            | 11.01.2021                | 7                        | 0 0 0 0 0                      | 0 0 0 0 0                      | —                        | —         | 20.01.2021               | 7                      | 13                    |
| 55-60| Male      | 07.01.2021            | 20.01.2021                | 13                       | 15 0 0 0 0                     | 0 0 0 0 0                      | —                        | —         | 20.01.2021               | 13                     | 3                     |
| 40-45| Male      | 04.01.2021            | 20.01.2021                | 16                       | 15 0 0 0 0                     | 0 0 0 0 0                      | —                        | —         | 20.01.2021               | 16                     | 0                     |
| 60-65| Female    | 02.01.2021            | 20.01.2021                | 18                       | 0 0 0 0 0                      | 0 0 0 0 0                      | —                        | —         | 20.01.2021               | 18                     | 0                     |
| 50-55| Male      | 18.01.2021            | 27.01.2021                | 9                        | 0 0 0 0 0                      | 0 0 0 0 0                      | 34, 34, 32, 13 ± 0, 32, 87 ± 0 | —         | 27.01.2021               | 9                      | 34 515                  |
| 55-60| Female    | 15.01.2021            | 27.01.2021                | 12                       | 15 0 0 0 0                     | 0 0 0 0 0                      | —                        | —         | 27.01.2021               | 12                     | 0                     |
| 60-65| Female    | 11.01.2021            | 27.01.2021                | 16                       | 0 0 0 0 0                      | 0 0 0 0 0                      | 37 66 37 66 37 66 37 66 37 | —         | 01.02.2021               | 21                     | 55 854                  |

*Manual reading of amplification curve. **Talking is measured in minutes, while the other behaviors are counted.
streptomycin/amphotericin B (PSA, Gibco) and transported to the lab on blue ice.

2.3. Quantification of Particle Concentrations. Particle concentrations were quantified using an AeroTrak 8220 (TSI, Shoreview, MN, US) optical particle counter (Model: 1300102), which was also placed at the foot end of the bed, at the same height as the air samplers. The AeroTrak was operated at a flow rate of 2.8 liters of air per minute (±5% accuracy) and binned particles as follows: 0.3–0.5, 0.5–1, 1–3, 3–5, 5–10, and >10 μm. Due to equipment malfunction, we only retrieved particle count data for 12 of the 13 patients.

2.4. Processing and RT-PCR of Air Samples. Air samples were thawed and vortexed, before removing filters from the lysis buffer using sterile forceps and placing them in sterile syringes to extract the remaining liquid back into the lysis buffer vial. Before RNA isolation with NucliSENS magnetic extraction reagents (BioMérieux), an internal control (LightMix Modular EAV RNA Extraction Control, TIB-MOLBIOL, Germany) was added (1 μl) to each sample. RNA isolation was performed with 90 μl silica suspension, otherwise according to the manufacturer’s protocol. RNA was eluted in 100 μl NucliSENS elution buffer prior to analysis with SARS-CoV-2 RT-PCR assays.

Quantification of SARS-CoV-2 RNA by RT-PCR was performed on a LightCycler 96 (Roche Diagnostics, Norway) using the LightCycler Multiplex RNA Virus Master (Roche Diagnostics, Norway) and the following primers and probes (Eurogentec, Belgium): RdRp nCoV IP2 and IP4 [37] from Pasture in duplex, and HKU (ORF1b-nsp14) with SARS-CoV-2 RT-PCR amplification reagents (BioMérieux), an internal control (LightMix Modular EAV RNA Extraction Control, TIB-MOLBIOL, Germany) was added (1 μl) to each sample. RNA isolation was performed with 90 μl silica suspension, otherwise according to the manufacturer’s protocol. RNA was eluted in 100 μl NucliSENS elution buffer prior to analysis with SARS-CoV-2 RT-PCR assays.

2.5. Cell Culture of Air Samples. Only samples that were RT-PCR positive (Ct value below LoD on either marker) were analyzed with cell culture assays. Vials with air filters were vortexed for 30 s before removal of the filters with sterile forceps. Fluid was extracted from the filters back into the vial as described in the RT-PCR procedure. African green monkey kidney cells (Vero E6, ATCC: CRL-1586) were used to culture the samples. Samples were incubated for 1 h at 37°C and 5% CO₂ atmosphere before removal, and the cells were maintained in DMEM (sigma) supplemented with 5% heat-inactivated fetal bovine (FBS, Gibco) serum and 1% PSA (Gibco). The cells were propagated in a humidified 37°C incubator in an atmosphere of 5% CO₂ for 6 days. 500 μl of supernatant was collected on days 3 and 6. After RNA isolation (NucliSENS Magnetic Extraction Reagents) RT-PCR was performed as described above.

2.6. Viral Load Quantification in Oropharyngeal Swabs from Hospitalized Patients. Oropharyngeal swabs were collected from 12 of the 13 patients in the pilot study. For eight of the patients, oropharyngeal swabs were taken on the same day as air samples were collected (Table 1). Oropharyngeal swabs (200 μl) were added to bacteriophage MS2 (Roche, Switzerland) as extraction/inhibition control and extracted using QiaAmp MinElute Virus Spin Kit (Qiagen, Germany). SARS-CoV-2 RNA real-time reverse transcriptase PCR targeting the viral envelope gene was done as described by Corman et al. [39] on the LightCycler 480 instrument (Roche). Cellular quantification in oropharyngeal samples was assessed using the cell control r-gene kit targeting the human cells.

2.7. Statistical Analyses. A Bayesian linear regression model (R; MCMCglmm: MCMCglmm [40]) was used to regress days since symptom onset on viral load from oropharyngeal samples. Default (weakly informative) priors were used. The analysis was performed with 20,000 MCMC iterations, a 5,000 burn-in, and a thinning interval of 10. Effective sample size, trace plots, and posterior distributions were used to assess model performance. 95% HDI (highest density interval) was reported for the parameter value. Significance was reported as pMCMC, which is two times the smaller of the MCMC estimates of the probability that a <0 or a >0, where a is the parameter value. Effect size and 95% CI was predicted with ggeffects:ggemmeans [41] for plotting.
Mean particle counts (per minute average) from three time periods were analyzed with linear models. The three-time periods are given as follows:

1. Control air sample period: a 15-minute period prior to administering NT, during which control air sampling was performed.

2. NT air sample period: a 15-minute period during which NT was given, and air sampling were performed.

3. NT period: a shorter period nested within the abovementioned “2. NT air sample period,” corresponding to the duration of the NT (which lasted approx. 10 minutes).

Separate analyses (R; stats: lm) were performed on each particle size bin (0.3–0.5, 0.5–1, 1–3, 3–5, 5–10, and >10 µm). Reference levels were set to particle counts from the control sample. \( P \) values are two-sided and considered significant at \( <0.05 \).
All statistical models and visualizations were produced in R v. 4.1.1 [42].

3. Results

3.1. Air Sample RT-PCR and Cell Culture. Only two air samples (from two patients) were SARS-CoV-2 positive, i.e., had one or more RT-PCR Ct values below the LoD (IP2/IP4 < 32, HKU < 35), both of which were collected during NT. The corresponding control air samples (collected before NT) for these same two patients had RT-PCR Ct values above LoD and were hence not considered positive (Table 1; Figure 1). Both patients were male, aged 50 and 61 years, and had experienced symptoms for nine and 11 days at the time of air sampling. The median for the other 11 patients was 13 days after symptom onset (Table 1).

In addition, two other patients had RT-PCR Ct values above LoD for the control air sample (Table 1) but neither of these patients had RT-PCR Ct values for the NT sample. SARS-CoV-2 was not cultured in any of the air samples.

3.2. Viral Load. Of the 13 patients, seven had detectable virus load in their oropharyngeal sample (for one patient data was not available); three had >34,000 copies (per human 1000 cells), one had 1,780 copies, and the remaining patients had <14 copies (Table 1). Of the three patients with high viral loads (>34,000 copies), two had positive NT air samples (i.e., RT-PCR Ct value below LoD) whereas one had an RT-PCR Ct value (i.e., below LoD). There was no significant association between the duration of symptoms and viral load in oropharyngeal samples (95% HDI = [-3909.45, 3465.99], pMCMC = 0.728; Figure 2).

3.3. Total Particle Concentrations. For particle sizes 0.3–0.5, 0.5–1, and 1–3 µm, concentrations were significantly higher during the NT air sampling period (15 minutes) and NT period (approx, 10 minutes; overlapping with NT air sampling period), than during the control sampling period (p ≤ 0.001; Table 2; Figure 3). For 3–5 µm particles there were significantly higher concentrations during the NT period than during the control sample period (p = 0.029; Table 2), while the NT air sample period (which lasted longer than the NT period; 15 minutes) was not significant for this size bin (p = 0.064; Table 2). There were no significant differences in particle concentrations for particles 5–10, and <10 µm (Table 2). All particle load distributions are shown in Figure 3. Analyzed data are given in Table 3.

4. Discussion

In this pilot study, we explored the effect of NT on the concentration of SARS-CoV-2 RNA and total particles in the air of COVID-19 patient isolation rooms. Only two air samples were positive (RT-PCR Ct values below LoD), both of which were sampled during NT. For all patients, we observed an increase in total concentrations of smaller particles (0.3–5 µm) during NT.

The two patients with positive air samples were both males, which is consistent with men generally having higher disease severity [43], and prolonged viral shedding [44] compared to women. They also had shorter symptom duration than patients with RT-PCR negative air samples. This is consistent with previous studies that have demonstrated that SARS-CoV-2 viral loads in the upper respiratory tract peak during the first week of illness and are followed by a consistent decline [45]. Symptom duration and viral load in
upper airways did not support such a pattern in our cohort (Figure 2); however, our analysis is limited by small sample size, only including two patients in the first week of illness and only three patients with a high viral load in the nasopharynx samples (Table 1).

As could be expected, we observed that patients with high viral load in the oropharynx disseminated more viral RNA into the air; the three patients with high viral loads (>34,000 copies per cell) included the two patients that had RT-PCR positive air samples collected during NT and one additional patient, whose control air sample (collected prior to NT) had an IP4 RT-PCR Ct value of 37.66. Of note, not all air and oropharynx samples were collected on the same day, which precluded direct comparisons for some samples. Finally, one patient had RT-PCR IP2/4 Ct values for the air sample collected prior to NT, and a viral load of zero copies in the oropharynx sample (samples were collected on the same day). This incongruity may be explained by upper respiratory sampling not being optimal for detecting lower respiratory tract infection [46], i.e., viral RNA in the air may have been disseminated from the lower respiratory tract, even though viral levels in the upper tract were too low for detection. The chosen patient sampling methodology, namely, oropharyngeal, is also less sensitive than combined nasopharynx/oropharynx sampling, which likely negatively affected detection levels in the patient samples [47].

Four patients had control sample RT-PCR Ct values above LoD. These included the two patients with positive NT air samples, but also two other patients with no Ct values for their NT air samples. Of these latter two patients, one had a viral load of >50,000, while the other had a viral load of zero (Table 1); however, as mentioned in the previous paragraph, the patient with a viral load of zero may have had an infection in the lower respiratory tract. Ct values were recorded for control samples and not NT samples can be due to viral concentrations in air being below LoD in both cases. Alternatively, the control sample Ct values may stem from room contamination or cross-contamination in the laboratory.

In our analysis, we opted to treat the three SARS-CoV-2 PCR markers separately, even though the three were run on all samples in parallel. There were two reasons for this approach: firstly, given the dilution effect in air and the high air exchange rate inside the isolation rooms, we expected the results to be near the LoD of the RT-PCR assays; secondly, different markers have different sensitivity—our air sample results demonstrated similar results to that reported for

### Table 2: Linear models comparing mean (per minute) particle counts during the control air sample period (15 minutes) with counts during the nebulizer therapy (NT) air sample period (15 minutes) and the nebulizer therapy period (approx, 10 minutes). Particle counts from the control air samples were set as the reference levels in the models.

| Predictors | Estimates | CI       | P   |
|------------|-----------|----------|-----|
| (Intercept| 7010.29   | −110238.05 to 124258.64 | <0.001 |
| NT air sample period | 35265.80 | 186841.61 to 518470.00 | <0.001 |
| NT period | 440291.92 | 274477.72 to 606106.11 | <0.001 |
| Observations | 36 | 0.498/0.467 | 0.5–0.5 µm |

| Predictors | Estimates | CI       | P   |
|------------|-----------|----------|-----|
| (Intercept| 525.00    | −44487.51 to 45537.50 | 0.001 |
| NT air sample period | 109909.43 | 46252.14 to 173566.72 | 0.001 |
| NT period | 143178.80 | 79521.51 to 206836.09 | <0.001 |
| Observations | 36 | 0.410/0.374 | 0.5–1 µm |

| Predictors | Estimates | CI       | P   |
|------------|-----------|----------|-----|
| (Intercept| 61.20     | −3317.85 to 3440.26 | 0.001 |
| NT air sample period | 9027.26  | 4248.55 to 13805.97 | <0.001 |
| NT period | 11636.99 | 6858.29 to 16415.70 | <0.001 |
| Observations | 36 | 0.450/0.417 | 1–3 µm |

| Predictors | Estimates | CI       | P   |
|------------|-----------|----------|-----|
| (Intercept| 5.47      | 1.57 to 9.37 | 0.064 |
| NT air sample period | 5.20   | −0.31 to 10.72 | 0.029 |
| NT period | 6.183     | 0.67 to 11.70 | 0.001 |
| Observations | 36 | 0.154/0.103 | 3–5 µm |

| Predictors | Estimates | CI       | P   |
|------------|-----------|----------|-----|
| (Intercept| 8.48      | 3.31 to 13.66 | 0.078 |
| NT air sample period | −0.99 | −8.31 to 6.32 | 0.494 |
| NT period | −2.49     | −9.80 to 4.83 | <0.001 |
| Observations | 36 | 0.014 to 0.045 | 5–10 µm |

| Predictors | Estimates | CI       | P   |
|------------|-----------|----------|-----|
| (Intercept| 2.77      | 1.54 to 4.00 | 0.738 |
| NT air sample period | −0.29 | −2.03 to 1.45 | 0.280 |
| NT period | −0.94     | −2.68 to 0.80 | 0.001 |
| Observations | 36 | 0.037 to 0.021 | >10 µm |
patient samples, with RdRp-IP2 and RdRp-IP4 appearing more sensitive than HKU [48].

The RT-PCR assay sensitivity test indicated a LoD of 2.2 virus copies per liter of air. Some other SARS-CoV-2 air studies report lower LoDs [49, 50]; however, while many studies do not report LoD in terms of viral concentrations in air, the lowest reported values across several SARS-CoV-2 air sampling studies indicate large variations in LoD [51].

Only two samples met the criteria for cell culture, which was a below LoD RT-PCR Ct value on any marker, but neither of these two samples were culture positive. This may be because replication-competent virus was not present in the samples; the patients in our pilot study had been ill for a long period of time and detectable virus may simply reflect remnant RNA and not infectious virus [45]. Isolation of infectious viruses has only rarely been possible from upper respiratory specimens later than 10 days after the start of symptoms [52]. Alternatively, loss of viability may have been inflicted during air sampling. Using a condensation growth air sampling method, that is potentially more gentle, Lednicky et al. [53] cultivated SARS-CoV-2 from a sample collected at 4.8 meters from one hospitalized COVID-19 patient; the patient in question had suffered from respiratory illness for only two days when air sampling was performed, which may also explain why SARS-CoV-2 was successfully cultured in this case.

Whether NT constitutes an AGP is a topic of contention [18, 19, 29–31, 33–35], which needs to be resolved given the potential implications for HCW safety. Clearly, NT generates aerosols by changing liquid medication to mist, but in medical terminology AGP implies the generation of aerosols from potentially infectious bodily fluids and tissues. In our pilot study, we were unable to demonstrate that SARS-CoV-2 RNA in the air during NT was from replication-competent virus. However, our results support the notion that NT may increase the dissemination of viral RNA from patient tissues and that aerosol particles from NT do not only come from aerosolized medication. Therefore, we recommend that HCW use airborne precautions when administering NT to patients, including filtering facepiece respirators equivalent to N95/FFP2 or higher, especially during the first period of illness when the patient is most likely to be infectious. Alternative methods for administrating aerosolized medication, that is likely to cause less contamination of the air, such as valved holding chambers, i.e., spacers with one-way valves that contain aerosol particles until inspiration occurs, may reduce the risk of transmission to HCW.

Our pilot study is limited by the relatively low number of air samples collected from patients with rather a long duration of COVID-19 and the low number of RT-PCR positive air samples. Furthermore, although sampling was performed before and during NT, the data are based on only two sampling points per patient and do not consider potential within-patient variability. The limited number of positives is likely due to the patient group, on average, being in the later stages of the disease, where viral loads in respiratory tissues decline [45]. Furthermore, it is likely that the high air exchange rate played a part in rapidly reducing aerosol concentrations of SARS-CoV-2 RNA in the isolation rooms where the pilot study was carried out [54]. Given the
low concentrations of viral RNA in air, we recommend that future studies sample for longer time periods than was used in the present pilot study.

We have shown that NT is associated with increased total aerosol particle concentrations for particles of sizes 0.3–5 μm. Although the dataset collected in this pilot study can only give preliminary information about the effect of NT, for two patients, we found SARS-CoV-2 RNA concentrations to increase in the surrounding air during NT. "X_his indicates that aerosols associated with NT are not simply a product of the administered medication but may also originate from the patient’s bodily fluids and tissues. Therefore, NT may involve an increased risk of infection for HCW. Given the importance of understanding the risks associated with NT, we recommend that similar studies be carried out with larger groups of patients that are at earlier stages of COVID-19.

Data Availability
The analyzed data are presented in Tables 1 and 3.

Additional Points

Practical Implications. In this pilot study, we found that nebulizer therapy increased the concentration of smaller particles (0.3–5 μm) and SARS-CoV-2 RNA in the air surrounding COVID-19 patients receiving such treatment. This is consistent with the notion that nebulizer therapy may increase the risk of exposure to SARS-CoV-2 for health care workers treating patients with COVID-19. Our results support the use of precautions against airborne infections when administering nebulizer therapy and that, if possible, less aerosol-producing nebulizer treatment modalities should be used. Furthermore, research is warranted to determine whether nebulizer therapy may increase the risk for transmission of replication-competent SARS-CoV-2.

Ethical Approval
The pilot study was approved by the Regional Committees for Medical and Health Research Ethics (REK) in South-

---

**Table 3: Mean (per minute) particle counts for 12 patients during the control air samples (15 minutes), during the nebulizer therapy (NT) air samples (15 minutes), and during nebulizer therapy (approx, 10 minutes).**

| Id | Sample type  | 0.3–0.5 μm | 0.5–1 μm | 1–3 μm | 3–5 μm | 5–10 μm | >10 μm |
|----|--------------|------------|----------|--------|--------|---------|--------|
| 1  | Control air sample | 13067      | 869      | 34     | 5      | 4       | 4      |
| 2  | NT air sample  | 444579     | 115319   | 9876   | 15     | 5       | 2      |
| 3  | NT            | 429120     | 114387   | 9994   | 15     | 4       | 2      |
| 4  | Control air sample | 26815      | 2312     | 119    | 11     | 8       | 4      |
| 5  | NT air sample  | 201995     | 49507    | 4271   | 10     | 5       | 1      |
| 6  | NT            | 222613     | 55080    | 4776   | 10     | 6       | 1      |
| 7  | Control air sample | 7571       | 376      | 34     | 3      | 3       | 2      |
| 8  | NT air sample  | 538017     | 178115   | 17476  | 21     | 5       | 2      |
| 9  | NT            | 683162     | 230186   | 22922  | 26     | 6       | 3      |
| 10 | Control air sample | 1279       | 156      | 64     | 10     | 6       | 2      |
| 11 | NT air sample  | 529887     | 177779   | 18094  | 21     | 6       | 2      |
| 12 | NT            | 623659     | 216669   | 23176  | 26     | 6       | 3      |
| 13 | Control air sample | 3349       | 332      | 38     | 1      | 5       | 1      |
| 14 | NT air sample  | 148372     | 57216    | 4409   | 1      | 4       | 1      |
| 15 | NT            | 156288     | 59386    | 4501   | 1      | 4       | 1      |
| 16 | Control air sample | 4669       | 352      | 207    | 8      | 42      | 8      |
| 17 | NT air sample  | 612392     | 179035   | 9988   | 9      | 32      | 7      |
| 18 | NT            | 704360     | 208721   | 11567  | 7      | 24      | 5      |
| 19 | Control air sample | 5214       | 359      | 52     | 2      | 12      | 6      |
| 20 | NT air sample  | 603217     | 221854   | 13962  | 2      | 15      | 8      |
| 21 | NT            | 1125716    | 444965   | 28720  | 2      | 5       | 2      |
| 22 | Control air sample | 642        | 60       | 7      | 1      | 1       | 0      |
| 23 | NT air sample  | 286782     | 87737    | 8489   | 9      | 2       | 1      |
| 24 | NT            | 342058     | 101785   | 9526   | 11     | 1       | 1      |
| 25 | Control air sample | 4149       | 276      | 29     | 4      | 3       | 2      |
| 26 | NT air sample  | 272819     | 63652    | 4984   | 7      | 3       | 1      |
| 27 | NT            | 317568     | 74987    | 5924   | 7      | 3       | 1      |
| 28 | Control air sample | 820        | 84       | 11     | 2      | 2       | 1      |
| 29 | NT air sample  | 286462     | 87245    | 8652   | 17     | 2       | 1      |
| 30 | NT            | 297897     | 91247    | 9011   | 17     | 2       | 1      |
| 31 | Control air sample | 4361       | 423      | 66     | 8      | 7       | 2      |
| 32 | NT air sample  | 62827     | 20787    | 2130   | 4      | 3       | 1      |
| 33 | NT            | 65840     | 21696    | 2205   | 4      | 3       | 1      |
| 34 | Control air sample | 12187     | 700      | 73     | 10     | 7       | 2      |
| 35 | NT air sample  | 328644     | 86969    | 6731   | 14     | 7       | 1      |
| 36 | NT            | 399344    | 105335   | 8157   | 14     | 7       | 1      |
Eastern Norway (reference no. 106624) and conducted in accordance with the Helsinki Declaration.

**Consent**

Inclusion was based on written, informed consent.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Authors’ Contributions**

JG designed and led the pilot study, performed the data analyses, and drafted the paper. KOB performed the RT-PCR analyses and contributed to the data management and writing. CG established the RT-PCR (HKU, IP2/IP4), and cell culture assays, and contributed to data management and writing. JCH and AMDR coordinated the SARS-CoV-2 cohort study and facilitated sampling coordination and data handling. BKG validated the quantification of viral load in oropharyngeal swabs and perform sample analyses. MFS collected data and contributed to coordination and data management. ABB contributed to the study design, coordination, and drafting of the paper. MD contributed to study design and coordination and supervised the pilot study. All authors contributed to the writing of the manuscript and approved the final version.

**Acknowledgments**

The pilot study was funded by the Norwegian Research Council (grant nos. 312688 and 312780), The Norwegian Defense Research Establishment (FFI), and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner.

**References**

[1] D. Cucinotta and M. Vanelli, "WHO declares COVID-19 a pandemic," *Acta BioMedica*, vol. 91, no. 1, pp. 157–160, 2020.
[2] "Worldometers. covid-19 coronavirus pandemic," 2021, https://www.worldometers.info/coronavirus/.
[3] N. C. Peeri, N. Shrestha, M. S. Rahman et al., "The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?" *International Journal of Epidemiology*, vol. 49, no. 3, pp. 717–726, 2020.
[4] A. Dinoi, M. Feltracco, D. Chirizzi et al., "A review on measurements of SARS-CoV-2 genetic material in air in outdoor and indoor environments: implication for airborne transmission," *Science of the Total Environment*, vol. 809, Article ID 151137, 2022.
[5] World Health Organization, *The Impact of COVID-19 on Health and Care Workers: A Closer Look at Deaths*, World Health Organization, Geneva, Switzerland, 2021.
[6] S. Bandypadhyay, R. E. Baticulon, M. Kadhum et al., "Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review," *BMJ Global Health*, vol. 5, no. 12, Article ID e003097, 2020.
[7] S. A. Gómez-Ochoa, O. H. Franco, L. Z. Rojas et al., "COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes," *American Journal of Epidemiology*, vol. 190, no. 1, pp. 161–175, 2021.
[8] L. H. Nguyen, D. A. Drew, M. S. Graham et al., "Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study," *The Lancet Public Health*, vol. 5, no. 9, pp. e475–e483, 2020.
[9] Y. Mahendradhata, N. L. P. E. Andayani, E. T. Haris et al., "The capacity of the Indonesian healthcare system to respond to COVID-19," *Frontiers in Public Health*, vol. 9, no. 887, Article ID 649819, 2021.
[10] World Health Organization Africa, *Only 1 in 4 African Health Workers Fully Vaccinated against COVID-19*, World Health Organization Africa, Geneva, Switzerland, 2021.
[11] C. S. Kow and S. S. Hasnan, "Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies," *Inflammopharmacology*, vol. 29, no. 4, pp. 1075–1090, 2021.
[12] J. Shapiro, N. E. Dean, Z. J. Madewell, Y. Yang, M. E. Halloran, and I. Longini, "Efficacy estimates for various COVID-19 vaccines: what we know from the literature and reports," *medRxiv*, 2021.
[13] T. Harder, J. Koch, S. Vygen-Bonnet et al., "Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021," *Euro Surveillance*, vol. 26, no. 28, Article ID 2100563, 2021.
[14] S. E. Fawcett, M. S. Madhusudhan, E. N. Gaddam et al., "Transmission risk of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) to healthcare personnel following unanticipated exposure to aerosol-generating procedures: experience from epidemiologic investigations at an academic medical center," *Infection Control & Hospital Epidemiology*, pp. 1–3, 2021.
[15] World Health Organization, *Infection Control Strategies for Specific Procedures in Health-Care Facilities*, WHO, Geneva, Switzerland, 2007.
[16] W. H. Seto, "Airborne transmission and precautions: facts and myths," *Journal of Hospital Infection*, vol. 89, no. 4, pp. 225–228, 2015.
[17] A. Davies, G. Thomson, J. Walker, and A. Bennett, "A review of the risks and disease transmission associated with aerosol generating medical procedures," *Journal of Infection Prevention*, vol. 10, no. 4, pp. 122–126, 2009.
[18] K. Tran, K. Cimon, M. Severn, C. L. Pessoa-Silva, and J. Conly, "Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review," *PLoS One*, vol. 7, no. 4, Article ID e35797, 2012.
[19] M. Klompas, M. Baker, and C. Rhee, "What is an aerosol-generating procedure?" *JAMA Surgery*, vol. 7, no. 4, Article ID e35797, 2021.
[20] G. S. Hamilton, "Aerosol-generating procedures in the COVID era," *Respirology*, vol. 26, no. 5, pp. 416–418, 2021.
[21] F. Hamilton, D. Arnold, B. R. Bzdek et al., "Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2?" *The Lancet Respiratory Medicine*, vol. 9, no. 7, pp. 687–689, 2021.
[22] R. L. Winslow, J. Zhou, E. F. Windle et al., "SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures," *Thorax*, vol. 77, no. 3, pp. 259–267, 2021.
[23] A. Brown, L. Schwarz, C. R. Counts et al., "Risk for acquiring coronavirus disease illness among emergency medical service
personnel exposed to aerosol-generating procedures,” Emerging Infectious Diseases, vol. 27, no. 9, pp. 2340–2348, 2021.

[24] N. M. Wilson, G. B. Marks, A. Eckhardt et al., “The effect of respiratory activity, non-invasive respiratory support and facemasks on aerosol generation and its relevance to COVID-19,” Anaesthesia, vol. 76, no. 11, pp. 1465–1474, 2021.

[25] C. C. Wang, K. A. Prather, J. Szmitman et al., “Airborne transmission of respiratory viruses,” Science, vol. 373, no. 6538, Article ID eab91949, 2021.

[26] D. K. Milton, “A rosetta stone for understanding infectious drops and aerosols,” Journal of the Pediatric Infectious Diseases Society, vol. 9, no. 4, pp. 413–415, 2020.

[27] Centers for Disease Control and Prevention, Interim Infection Prevention and Control Recommendations for Healthcare Personnel during the Coronavirus Disease 2019 (COVID-19) Pandemic, Atlanta, GA, USA, 2021.

[28] F. Belosi, M. Conte, V. Gianelle, G. Santachiara, and D. Contini, “On the concentration of SARS-CoV-2 in outdoor air and the interaction with pre-existing atmospheric particles,” Environmental Research, vol. 193, Article ID 110603, 2021.

[29] G. H. Wan, Y. H. Tsai, Y. K. Wu, and K. C. Tsao, “A large-volume nebulizer would not be an infectious source for severe acute respiratory syndrome,” Infection Control & Hospital Epidemiology, vol. 25, no. 12, pp. 1113–1115, 2004.

[30] Government of UK, “Covid-19: infection prevention and control (ipc),” 2021, https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control.

[31] R. Swarnakar, N. M. Gupta, I. Halder, and G. C. Khilnani, “ICS guidance for nebulization during the COVID-19 pandemic,” Lung India, vol. 38, no. 7, 2020.

[32] D. S. C. Hui, M. T. V. Chan, and B. Chow, “Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers,” Hong Kong Medical Journal, vol. 20, no. 4, pp. 9–13, 2014.

[33] I. Amirav and M. T. Newhouse, “Transmission of coronavirus by nebulizer: a serious, underappreciated risk,” Canadian Medical Association Journal, vol. 192, no. 13, p. E346, 2020.

[34] A. Ari, “Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19,” Respiratory Medicine, vol. 167, Article ID 105987, 2020.

[35] S. Sethi, I. Z. Barjaktarevic, and D. P. Tashkin, “The use of nebulized pharmacotherapies during the COVID-19 pandemic,” Therapeutic Advances in Respiratory Disease, vol. 14, Article ID 17534662095436, 2020.

[36] J. C. Holter, S. E. Pischke, E. de Boer et al., “Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients,” Proceedings of the National Academy of Sciences, vol. 117, no. 40, pp. 25018–25025, 2020.

[37] World Health Organization, Protocol: Real-Time RT-PCR Assays for the Detection of SARS-CoV-2, Institut Pasteur, Paris, France, 2020.

[38] D. K. W. Chu, Y. Pan, S. M. S. Cheng et al., “Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia,” Clinical Chemistry, vol. 66, no. 4, pp. 549–555, 2020.

[39] V. M. Gorman, O. Landt, M. Kaiser et al., “Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,” Euro Surveillance, vol. 25, no. 3, Article ID 2000045, 2020.

[40] J. D. Hadfield, “MCMC methods for multi-response generalized linear mixed models: the MCMCglmm R package,” Journal of Statistical Software, vol. 33, no. 2, pp. 1–22, 2010.

[41] L. Daniel, “ggeffects/Tidy data frames of marginal effects from regression models,” Journal of Open Source Software, vol. 3, no. 26, p. 772, 2018.

[42] R Development Core Team, R: A Language and Environment for Statistical Computing, Foundation for Statistical Computing, Vienna, Austria, 2022.

[43] H. Jacobsen and S. L. Klein, “Sex differences in immunity to viral infections,” Frontiers in Immunology, vol. 12, no. 3483, Article ID 720952, 2021.

[44] K. Xu, Y. Chen, J. Yuan et al., “Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19),” Clinical Infectious Diseases, vol. 71, no. 15, pp. 799–806, 2020.

[45] M. Cevik, M. Tate, O. Lloyd, A. E. Mararolo, J. Schafers, and A. Ho, “SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis,” The Lancet Microbe, vol. 2, no. 1, pp. e13–e22, 2021.

[46] K. Murphy, “SARS CoV-2 detection from upper and lower respiratory tract specimens: diagnostic and infection control implications,” Chest, vol. 158, no. 5, pp. 1804–1805, 2020.

[47] K. Sharma, P. Aggarwala, D. Gandhi et al., “Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using rRT-PCR in new and follow up cases of COVID-19 infection: quest for the best choice,” PLoS One, vol. 16, no. 4, Article ID e0249408, 2021.

[48] S. Ettevant, A. Bal, V. Escuret et al., “Performance assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories,” Journal of Clinical Medicine, vol. 9, no. 6, p. 1871, 2020.

[49] A. X. Y. Ang, I. Luhung, B. A. Ahidjo et al., “Airborne SARS-CoV-2 surveillance in hospital environment using high-flowrate air samplers and its comparison to surface sampling,” Indoor Air, vol. 32, no. 1, Article ID e12930, 2022.

[50] M. Conte, M. Feltracco, D. Chirizzi et al., “Airborne concentrations of SARS-CoV-2 in indoor community environments in Italy,” Environmental Science and Pollution Research, vol. 29, no. 10, 2021.

[51] J. W. Cherrie, M. P. C. Cherrie, A. Davis et al., “Contamination of air and surfaces in workplaces with SARS-CoV-2 virus: a systematic review,” Annals of Work Exposures and Health, vol. 65, no. 8, 2021.

[52] K. A. Walsh, S. Spillane, L. Comber et al., “The duration of infectiousness of individuals infected with SARS-CoV-2,” Journal of Infection, vol. 81, no. 6, pp. 847–856, 2020.

[53] J. A. Lednicky, M. Lauzardo, Z. H. Fan et al., “Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,” International Journal of Infectious Diseases, vol. 100, pp. 476–482, 2020.

[54] A. Fadaei, “Ventilation systems and COVID-19 spread: evidence from a systematic review study,” European Journal of Sustainable Development Research, vol. 5, no. 2, Article ID em0157, 2021.